NASDAQ · TXMD
TherapeuticsMD, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TXMD: Nov 11, 2026
TherapeuticsMD, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $0.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Zacks- RTTNews · Oct 16, 1:19 AM EDTMayne Pharma Agrees To Settle IMVEXXY Patent Litigation With Teva Pharmaceutical(RTTNews) – On Friday, Mayne Pharma Group Ltd., (MYX.AX) said it has agreed to settle U.S. patent litigation with Teva Pharmaceuticals USA (TEVA) concerning IMVEXXY, its estradiol vaginal inserts for treating moderate to severe dyspareunia due to menopause.
- RTTNews · Aug 25, 1:13 PM EDTTherapeuticsMD Reports Q2 2026 Results, License Revenue Declines; Evaluates Strategic Alternatives(RTTNews) – TherapeuticsMD, Inc. (TXMD), a pharmaceutical royalty company focused on collecting royalties from licensed products, reported financial results for the second quarter ended June 30, 2026.
- RTTNews · Jun 14, 10:02 PM EDTTop Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch(RTTNews) – Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst expected in the second half of 2026; and Alumis, which is advancing its lead th
- RTTNews · Jan 7, 10:14 PM ESTAfter-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates(RTTNews) – Several biotechnology and healthcare companies posted notable gains in after-hours trading on Wednesday, driven by clinical updates, financial results, and upcoming industry presentations.
- The Motley Fool · Aug 12, 10:57 PM EDTTherapeuticsMD Swings to Profit in Q2Net income from continuing operations turned positive, reaching $0.05 per basic and diluted common share for Q2 2025 (GAAP), compared to a $(0.09) loss per share a year earlier.
- RTTNews · Aug 12, 4:44 PM EDTTherapeuticsMD Q2 Earnings Summary(RTTNews) – Below are the earnings highlights for TherapeuticsMD (TXMD):
- Zacks · Apr 14, 12:00 PM EDTAll You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to BuyInvestors might want to bet on TherapeuticsMD (TXMD), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates — one of the most powerful forces impacting stock prices — has triggered this rating change.
- RTTNews · Mar 9, 7:30 AM ESTPre-market Movers: TORO, SI, AMBI, BCAN, SIVB…(RTTNews) – The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET).
- RTTNews · Jan 3, 7:27 AM ESTTherapeuticsMD Grants Mayne Pharma License To Commercialize Its Products In US(RTTNews) – TherapeuticsMD Inc. (TXMD) Tuesday announced that it has completed its previously announced transaction to license its products to Mayne Pharma Group Ltd., an Australian specialty pharmaceutical company.
- RTTNews · Dec 4, 8:03 PM ESTTherapeuticsMD To License Its Products To Mayne Pharma(RTTNews) – TherapeuticsMD Inc. (TXMD) said that it has entered into agreements to license its products to an affiliate of Australia's Mayne Pharma Group Limited for commercialization in the United States.
- Zacks · Nov 14, 7:55 PM ESTTherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue EstimatesTherapeuticsMD (TXMD) came out with a quarterly loss of $3.13 per share versus the Zacks Consensus Estimate of a loss of $2.04. This compares to loss of $5.50 per share a year ago. These figures are adjusted for non-recurring items.
- Zacks · Nov 9, 5:45 PM ESTOrganogenesis (ORGO) Lags Q3 Earnings and Revenue EstimatesOrganogenesis (ORGO) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for TherapeuticsMD, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.